Navigation Links
Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
Date:8/16/2011

generation (wet AMD), central retinal vein occlusion (CRVO), diabetic macular edema (DME), and other eye diseases and disorders.  Bayer submitted an application for marketing authorization in Europe in wet AMD in June 2011.

Bayer HealthCare will market EYLEA™ (aflibercept injection) outside the United States, where the companies will share equally the profits from any future sales of EYLEA.  Regeneron maintains exclusive rights to EYLEA in the United States.

Conference Call InformationLeonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, and other members of senior management will host a conference call to discuss the extension of the review period for EYLEA BLA for the treatment of patients with wet AMD, as well as other corporate matters.  The interactive call will be held on August 17, 2011 at 8:30 a.m. Eastern Time and can be accessed live through the Regeneron website at www.regeneron.com on the Investor Relations page.  The call, including the question and answer session, can also be accessed by dialing:

Domestic Dial-in Number: (888) 660-6127

International Dial-in Number: (973) 890-8355

Participant Passcode: 92316573

An archived version of the conference call will be available for 30 days on the company's website at www.regeneron.com on the Investor Relations page.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
2. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
3. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
6. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
7. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
8. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
9. Anesiva Announces Second Quarter 2008 Financial Results and Update
10. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
11. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  ECC West Africa, LLC (ECC) signed ... with University College Hospital (UCH) Ibadan Board of Management ... finance, design, construct, and operate and maintain a new, ... . Under the first of the 4-phase project, ECC ... funding applications. UCH Ibadan intends to finance and develop ...
(Date:7/24/2014)... computers have yet to materialise. Yet, scientists are ... such computers faster. One such approach relies on ... by applying an electric field. A new study ... coupled quantum dots (TQDs) with electrical impulses can ... example, should TQDs be used as quantum information ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)... July 24, 2014 SRI International has been ... National Institute of Allergy and Infectious Diseases (NIAID), part ... development of potential therapies for HIV infection and AIDS. ... HIV and AIDS and the complications and opportunistic infections ... preventing sexual transmission of HIV. According ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... Health Robotics today announced,audited results for FY2008 ending ... orders, revenue, earnings and cash flow. , ... million, a 161% increase year-over-year as,the company began ... indirect,sales-channel franchise fee model, recurring revenue recognition, zero ...
... MESA, Calif., April 14 Oxygen Biotherapeutics, ... it has reached a development and commercial ... One(R) Global Pharmaceutical Services business unit to ... perfluorocarbon (PFC) therapeutic oxygen carrier. Oxycyte will ...
... April 14 BioVex Inc, a company developing ... and infectious disease, announced today that its OPTiM (OncoVEX Pivotal ... previously treated patients with Stage III and Stage IV melanoma ... U.S. with sites in the United Kingdom, Germany and Australia ...
Cached Biology Technology:Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 2Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 3Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 4Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 5Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs 2BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 2BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 3BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 4
(Date:7/28/2014)... killers to prevent and treat HIV infection has been ... these molecules can arouse as they get rid of ... the Weizmann Institute and the National Institutes of Health ... molecules interferons around the time of infection ... disease. Their research appeared in Nature . ...
(Date:7/28/2014)... RENO Norwegian explorer Roald Amundsen became the first ... 1911. More than 100 years later, an international team ... Research Institute (DRI) have proven that air pollution from ... 16 ice cores collected from widely spaced locations around ... created the most accurate and precise reconstruction to date ...
(Date:7/27/2014)... Scientists have discovered a new species of mayfly in the ... of India. In fact, this is the first time that ... been collected in peninsular India. , The new species, called ... T. Soldan for his substantial contribution to the understanding of ... authors of a study that describes the new mayfly in ...
Breaking Biology News(10 mins):Interfering with interferon 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
... new gasoline. But where,s the nearest "gas" station ... vehicle? Will hydrogen stations be strategically convenientlocated on ... What marketing development obstacles need to be overcome if ... and gain widespread acceptance? According to an article ...
... the effect of nutrients on muscle maintenance in the hope ... we get old. The researchers, based at the School ... know what sort of exercise we can take and what ... of skeletal muscle with ageing. The team from the ...
... from Tel Aviv University, the saying may be more than ... have an ability to "see" colors and shapes with their ... of a new book, Advances in Information Optics and ... optical imaging technology that beats the limitations of today,s lens-based ...
Cached Biology News:The viability of hydrogen transportation markets: Chicken or egg? 2A stronger future for the elderly 2Seeing through the skin 2
... medium was originally formulated to support the ... emperor gum moth,Antherea eucalypti. The medium is ... closely resembleAnthereahemolymph. The cell lines established by ... continuous lines developed. The basal medium, when ...
... all Programmable and Digital Orbital Shaker. Our durable, ... to make every day use even easier. This ... up to 4 different programs. Its easy recall ... Furthermore, the VSOS-4P has a pulse operation for ...
... MONOLIGHT 3096 Microplate Luminometer has been ... bioluminescence and for,all measurements of glow ... reactions where the light remain nearly ... as well as for very fast ...
... Adept CE 4100 high pressure pump ... precision, with software drive compensation, reducing pulsing ... are selectable in 0.001mL steps. , The ... and bio-compatible., Pumps may be programmed from ...
Biology Products: